Vaxcyte, Inc. (NASDAQ:PCVX) SVP Mikhail Eydelman Sells 5,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $109.27, for a total transaction of $546,350.00. Following the sale, the senior vice president now directly owns 28,623 shares in the company, valued at $3,127,635.21. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $111.75 on Wednesday. The company has a market capitalization of $12.47 billion, a P/E ratio of -26.11 and a beta of 0.99. Vaxcyte, Inc. has a 52-week low of $44.20 and a 52-week high of $121.06. The company’s 50 day moving average price is $95.66 and its 200-day moving average price is $79.73.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter last year, the company posted ($0.70) earnings per share. Analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PCVX. Darwin Global Management Ltd. lifted its position in shares of Vaxcyte by 374.3% during the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after acquiring an additional 2,170,845 shares during the period. Vanguard Group Inc. lifted its position in shares of Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after acquiring an additional 1,284,883 shares during the period. Capital Research Global Investors lifted its position in shares of Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after acquiring an additional 700,414 shares during the period. Janus Henderson Group PLC lifted its position in shares of Vaxcyte by 9.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after acquiring an additional 692,492 shares during the period. Finally, Avoro Capital Advisors LLC acquired a new position in shares of Vaxcyte during the 1st quarter valued at $39,278,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

PCVX has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Bank of America lifted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC lifted their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.